Lessons from a BACE1 inhibitor trial: Off‐site but not off base

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Alzheimer's & Dementia

• Publication date

  2014-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jalz.2013.11.004PMID 24530026PMCID PMC4205206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Idiosyncratic drug-induced liver injury: an update on the 2007 overview

  2014cited by this paper
• Autism as early neurodevelopmental disorder: evidence for an sAPPα-mediated anabolic pathway

  2013cited by this paper
• Drug-induced liver injury: mechanisms, types and biomarkers.

  2013cited by this paper
• Functional microRNAs in Alzheimer’s disease and cancer: differential regulation of common mechanisms and pathways

  2013cited by this paper
• Dual Cleavage of Neuregulin 1 Type III by BACE1 and ADAM17 Liberates Its EGF-Like Domain and Allows Paracrine Signaling

  2013cited by this paper
• MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects*

  2013cited by this paper
• 2013 Alzheimer's disease facts and figures

  2013cited by this paper
• Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles

  2013cited by this paper
• Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes

  2013cited by this paper
• Current Challenges and Controversies in Drug-Induced Liver Injury

  2012cited by this paper
• Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders.

  2012cited by this paper
• Alzheimer mechanisms and therapeutic strategies.

  2012cited by this paper
• Prions: a piece of the puzzle?

  2012cited by this paper
• New and emerging treatments for Alzheimer's disease

  2012cited by this paper
• Metabolic activation in drug-induced liver injury

  2012cited by this paper
• MicroRNA-153 Physiologically Inhibits Expression of Amyloid-β Precursor Protein in Cultured Human Fetal Brain Cells and Is Dysregulated in a Subset of Alzheimer Disease Patients*

  2012cited by this paper
• Targets for AD treatment: conflicting messages from γ‐secretase inhibitors

  2011cited by this paper
• Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons

  2011cited by this paper
• Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

  2011cited by this paper
• Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

  2011cited by this paper
• MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed.

  2011cited by this paper
• Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice

  2011cited by this paper
• Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

  2011cited by this paper
• Drug-induced liver injury.

  2010cited by this paper
• Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review

  2010cited by this paper
• Why so few drugs for Alzheimer's disease? Are methods failing drugs?

  2010cited by this paper
• MicroRNAs: Target Recognition and Regulatory Functions

  2009cited by this paper
• The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

  2009cited by this paper
• Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion in vivo.

  2009cited by this paper
• The perils of Alzheimer's drug development.

  2009cited by this paper
• The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases

  2009cited by this paper
• Protein Sialylation by Sialyltransferase Involves Radiation Resistance

  2008cited by this paper
• Many drugs and phytochemicals can be activated to biological reactive intermediates.

  2008cited by this paper
• Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing.

  2008cited by this paper
• Alzheimer's Disease (AD)-Like Pathology in Aged Monkeys after Infantile Exposure to Environmental Metal Lead (Pb): Evidence for a Developmental Origin and Environmental Link for AD

  2008cited by this paper
• Drug-induced liver injury in 2007

  2008cited by this paper
• The Human Protein Atlas—a tool for pathology

  2008cited by this paper
• Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional β-secretase candidate(s)

  2008cited by this paper
• How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD.

  2007cited by this paper
• BACE1 gene promoter is differentially regulated

  2007cited by this paper
• Effectiveness of siRNA uptake in target tissues by various delivery methods.

  2007cited by this paper
• Toxicophores: investigations in drug safety.

  2006cited by this paper
• Intracellular signaling mechanisms of acetaminophen-induced liver cell death.

  2006cited by this paper
• Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

  2006cited by this paper
• Acute Hepatitis Due to Shen-Min: A Herbal Product Derived From Polygonum multiflorum

  2006cited by this paper
• Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors.

  2006cited by this paper
• Bace1 modulates myelination in the central and peripheral nervous system

  2006cited by this paper
• In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase.

  2005cited by this paper
• In Vivo Cleavage of α2,6-Sialyltransferase by Alzheimer β-Secretase*

  2005cited by this paper
• A comprehensive listing of bioactivation pathways of organic functional groups.

  2005cited by this paper
• Gene structure and organization of the human beta-secretase (BACE) promoter.

  2004cited by this paper
• Age‐related changes in serum melatonin in mice: higher levels of combined melatonin and 6‐hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues

  2004cited by this paper
• Gene structure and organization of the human β‐secretase (BACE) promoter

  2004cited by this paper
• Functional characterization of the 5′ flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression

  2004cited by this paper
• BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes.

  2003cited by this paper
• The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers.

  2002cited by this paper
• Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase

  2001cited by this paper
• Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase.

  2001cited by this paper
• Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

  2001cited by this paper
• Role of quinones in toxicology.

  2000cited by this paper
• A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer’s amyloid precursor protein β-secretase

  2000influential reference
• Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype.

  1999cited by this paper
• Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

  1999cited by this paper
• Alzheimer’s Dementia

  1985cited by this paper

• Is the Era of One-Size-Fits-All Alzheimer’s Treatment Officially Over?

  2025cites this paper
• Moleküler Kenetlenme Simülasyonları ile Yeni Aday BACE-1 İnhibitörü Tasarımı

  2025cites this paper
• A Novel RAGE Modulator Induces Soluble RAGE to Reduce BACE1 Expression in Alzheimer's Disease

  2025cites this paper
• BACE1: Biological Functions and Involvement in the Pathophysiology of Alzheimer's Disease and Other Neurological Disorders

  2025cites this paper
• Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein

  2024cites this paper
• The Tao Hong Si Wu Decoction ameliorates diabetes‐associated cognitive dysfunction by inhibiting the formation of amyloid plaques

  2024cites this paper
• Discovery of novel imidazolyl-6,7-dimethoxyisoquinoline derivatives as promising BACE1 inhibitors for management of Alzheimer's disease

  2024cites this paper
• Bacopa monnieri phytochemicals as promising BACE1 inhibitors for Alzheimer’s disease therapy

  2024cites this paper
• BACE1 inhibitors from the fruits of Alpinia oxyphylla have efficacy to treat T2DM-related cognitive disorder.

  2024cites this paper
• Disease-modifying vs symptomatic treatments: Splitting over lumping.

  2023cites this paper
• Discovery of a Small-Molecule Modulator of the Autophagy-Lysosome Pathway That Targets Lamin A/C and LAMP1, Induces Autophagic Flux, and Affects Lysosome Positioning in Neurons

  2023cites this paper
• Identifying β-secretase 1 (BACE1) inhibitors from plant-based compounds: an approach targeting Alzheimer’s therapeutics employing molecular docking and dynamics simulation

  2023cites this paper
• Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloid‐β Cascade: Pros and Cons of Chemical and Biological Modalities

  2023cites this paper
• Chronic basal forebrain activation improves spatial memory, boosts neurotrophin receptor expression, and lowers BACE1 and Aβ42 levels in the cerebral cortex in mice.

  2023cites this paper
• Therapeutic nanotechnologies for Alzheimer's disease: a critical analysis of recent trends and findings.

  2022cites this paper
• The emerging role of furin in neurodegenerative and neuropsychiatric diseases

  2022cites this paper
• Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach

  2022cites this paper
• Novel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer's disease.

  2022cites this paper
• Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics

  2022cites this paper
• Cholinergic forebrain activation improves cognition, boosts neurotrophin receptors, and lowers Aβ42 levels in the cerebral cortex of 5xFAD mice

  2022influential citation
• Effects of microRNA-298 on APP and BACE1 translation differ according to cell type and 3′-UTR variation

  2022cites this paper
• Human microRNA (miR-20b-5p) modulates Alzheimer’s disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer’s biomarkers

  2022cites this paper
• Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures

  2021cites this paper
• Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer’s Disease: A Review Study

  2021cites this paper
• The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice.

  2021cites this paper
• Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review

  2021cites this paper
• Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures

  2021cites this paper
• Structural biology of cell surface receptors implicated in Alzheimer’s disease

  2021cites this paper
• Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives

  2020cites this paper
• Peli1 impairs microglial Aβ phagocytosis through promoting C/EBPβ degradation

  2020cites this paper
• Neuronal deficiency of p38α‐MAPK ameliorates symptoms and pathology of APP or Tau‐transgenic Alzheimer’s mouse models

  2020cites this paper
• Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission

  2020cites this paper
• MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties

  2020cites this paper
• Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing

  2020cites this paper
• Is It the Twilight of BACE1 Inhibitors?

  2020cites this paper
• Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy

  2020cites this paper
• What Can Economics Say about Alzheimer's Disease?

  2020cites this paper
• The physiological processing of Alzheimer-associated amyloid beta precursor protein in human and animal-derived neuronal models

  2020cites this paper
• A Novel Cell-based β-secretase Enzymatic Assay for Alzheimer's Disease.

  2019cites this paper
• A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

  2019cites this paper
• Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?

  2019cites this paper
• New evolutions in the BACE1 inhibitor field from 2014 to 2018.

  2019cites this paper
• A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

  2019cites this paper
• Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.

  2019cites this paper
• Computational Drug Repurposing for Neurodegenerative Diseases

  2019cites this paper
• Beta secretase 1-dependent amyloid precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling

  2019cites this paper
• Fluoro-benzimidazole derivatives to cure Alzheimer's disease: In-silico studies, synthesis, structure-activity relationship and in vivo evaluation for β secretase enzyme inhibition.

  2019cites this paper
• Chapter 8 Present and Future Therapies for Alzheimer ’ s Disease

  2019cites this paper
• Protoilludane, Illudalane, and Botryane Sesquiterpenoids from the Endophytic Fungus Phomopsis sp. TJ507A.

  2018cites this paper
• Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer’s disease

  2018cites this paper
• Alzheimer's Disease: Advances in Drug Development.

  2018cites this paper
• L-Norvaline, a new therapeutic agent against Alzheimer’s disease

  2018cites this paper
• Present and Future Therapies for Alzheimer’s Disease

  2018cites this paper
• BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains

  2018cites this paper
• BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology

  2018cites this paper
• The amyloid hypothesis is too good to be true

  2017cites this paper
• Inhibition of γ-Secretase Leads to an Increase in Presenilin-1

  2017cites this paper
• Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.

  2017cites this paper
• Calycosin improves cognitive function in a transgenic mouse model of Alzheimer's disease by activating the protein kinase C pathway

  2017cites this paper
• Decrease in the Generation of Amyloid-β Due to Salvianolic Acid B by Modulating BACE1 Activity.

  2017cites this paper
• Molecular Targets of Tannic Acid in Alzheimer's Disease.

  2017cites this paper
• α‐Mangostin decreases β‐amyloid peptides production via modulation of amyloidogenic pathway

  2017cites this paper
• Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay.

  2016cites this paper
• Alzheimer's therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies.

  2016cites this paper
• The microrna-mediated regulation of proteins implicated in the pathogenesis of Alzheimer's Disease

  2016cites this paper
• Alzheimer Disease: Various Therapeutic Interventions and Alternative under Clinical Trial

  2016cites this paper
• Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein.

  2016cites this paper
• Specific Inhibition of b-Se cretase Processing of the Alzheimer Disease Amyloid Precursor Protein

  2016influential citation
• Recent Developments in Understanding Brain Aging: Implications for Alzheimer's Disease and Vascular Cognitive Impairment.

  2016cites this paper
• Therapeutic strategies for Alzheimer’s disease in clinical trials

  2016cites this paper
• Epigenetics of dementia: understanding the disease as a transformation rather than a state.

  2016cites this paper
• Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

  2016cites this paper
• Specific Inhibition of bSe cretase Processing of the Alzheimer Disease Amyloid Precursor Protein Graphical

  2016cites this paper
• An Integrated Approach for Fragment‐Based Lead Discovery: Virtual, NMR, and High‐Throughput Screening Combined with Structure‐Guided Design. Application to the Aspartyl Protease Renin.

  2016cites this paper
• Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases

  2015cites this paper
• Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

  2015cites this paper
• Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.

  2015cites this paper
• Prospects of β‐Secretase Inhibitors for the Treatment of Alzheimer’s Disease

  2015cites this paper
• Inhibition of Alzheimer’s BACE-1 by 2,6-dialkyl-4-chromon-3-yl-1,4-dihydropyridine-3,5-dicarboxylates

  2015cites this paper
• View of excellent ROAD from the CAR.

  2015cites this paper
• The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease

  2015cites this paper
• Update on Alzheimer’s Disease

  2015cites this paper
• Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer's Disease.

  2015cites this paper
• Significance of transcytosis in Alzheimer's disease: BACE1 takes the scenic route to axons

  2015cites this paper
• Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice

  2015cites this paper
• Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.

  2014cites this paper
• Intravenous Immunoglobulin (IVIG) Treatment Exerts Antioxidant and Neuropreservatory Effects in Preclinical Models of Alzheimer’s Disease

  2014cites this paper
• Cdk5 activity in the brain – multiple paths of regulation

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

  2014cites this paper
• Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond.

  2014cites this paper
• Strategizing the Development of Alzheimer’s Therapeutics

  2014cites this paper
• MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects*

  2013cites this paper
• Spatiotemporal activation of the C/EBP beta/delta-secretase axis regulates the pathogenesis of Alzheimer's disease

  year unknowncites this paper